Bamlanivimab, Etesevimab Combination Reduced COVID-19-Related Fatality, Hospitalization Rates Among High-Risk Ambulatory Patients, Data Show

Healio (7/14, Dreisbach) reports, “The monoclonal antibody cocktail of bamlanivimab plus etesevimab reduced the risk for COVID-19-related death and hospitalization among high-risk ambulatory patients compared with placebo, according to” late-stage data pu...